ChronoScale Holdings Corp 2026: Revenue $41.48M, EPS ($0.29) — 10-Q Summary

ChronoScale Holdings Corp (CHRN) reported Q2 2026 revenue of $41.48M, up 148% YoY, but posted a net loss of $42.48M and EPS of ($0.29). Growth was driven by new customers and hardware resale. The company expanded its Cloud GPU-as-a-Service, secured partnerships, and restructured its business.

Original reporting
Published Oct 14, 2026, 8:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ChronoScale Holdings Corp 2026: Revenue $41.48M, EPS ($0.29) — 10-Q Summary — source image
Decision brief

The 30-second read

$CHRNBearishLow
01

Why it matters

The earnings miss may trigger short‑term sell pressure, but the sizable pre‑payment backlog and hardware expansion could mitigate long‑term risk.

02

Market read

Primary earnings disclosure for a micro‑cap; modest trading relevance due to loss magnitude.

03

What to watch

The $328.2M in customer pre‑payments and new NVIDIA H100 capacity could support future revenue growth.

Relevance 6/10Novelty 6/10Timing: after-hours release

Background

ChronoScale Holdings Corp filed a 10‑Q reporting a 148% revenue increase year‑over‑year but a deep net loss, while announcing new GPU capacity and strategic partnerships.

Company-level read

Ticker impact

$CHRNBearishMedium confidence
Context

ChronoScale Holdings Corp disclosed its Q4 2026 results with revenue of $41.48M and a net loss of $42.48M, a fresh 10‑Q filing.

Expected impact

likely pressure as the market prices in the unexpected loss

Evidence & confidence

Earnings miss and large net loss for a micro‑cap typically trigger sell‑offs, especially without offsetting guidance.

Market effects

Highlights volatility in the niche AI‑cloud services sector as smaller players report earnings.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global impact; primarily a company‑specific event.

Counterpoint

If the pre‑payment pipeline holds, the loss may be temporary and could present a buying opportunity.

Key entities

  • ChronoScale Holdings Corp

    Micro‑cap AI cloud services provider.

  • Microsoft

    Strategic partnership announced.

  • Nutanix

    Strategic partnership announced.

Related articles

$SLNHMed

Soluna and Applied Digital to build 50 MW wind-powered AI data center in Texas

Soluna (SLNH) and Applied Digital (APLD) agreed to form a joint venture to build a 50 MW wind-powered AI data center in Texas. Applied will own 51%, providing capital, while Soluna contributes land and power assets. ChronoScale (CHRN), majority-owned by Applied, may lease the facility. The project is expected to close by year-end, with Phase 1 powered by Soluna's Briscoe Wind Farm and the grid.

$CHRNMedAI 8/10

ChronoScale Reports Fiscal First Quarter 2027 Results

ChronoScale Holdings Corp (CHRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ChronoScale Reports Fiscal First Quarter 2027 Results MENLO PARK, Calif. – October 15, 2026 — ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence

$CHRNMed

ChronoScale Expands AI Pipeline With $1 Billion Revenue Run Rate In Sight

ChronoScale Holdings (CHRN) shares rose after expanding AI infrastructure contracts, projecting a $1 billion annualized revenue run rate by Q3 2027. The company also completed the sale of its Ekso Bionics business. CHRN is trading at $20.33, above its 20-day and 100-day SMAs but below the 50-day SMA. Analysts rate CHRN as Strong Buy with an average price target of $32.

$CHRNHighAI 8/10

ChronoScale stock jumps on $1B revenue target from AI deals

ChronoScale Corp (CHRN) shares rose 3% after-hours after announcing deals expected to reach $1B annualized revenue run rate by Q3 2027. The AI infrastructure provider signed a contract extension and new customer agreement, though revenue is subject to deployment and capital risks. The company also sold its Ekso Bionics unit to focus on core AI infrastructure business.